TUESDAY, April 15, 2025 (HealthDay News) — Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury. The company said the injury went away after the person stopped taking the drug, called danuglipron, The Associated Press reported. The pill was in […]
The post Pfizer Ends Testing of Obesity Pill After Possible Liver Injury first appeared on Physician’s Weekly.
